Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis
Public ClinicalTrials.gov record NCT00179478. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Controlled High-risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurologic Surveillance (CHAMPIONS10)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The current study is a continuation of the 5 year extension study of the phase III CHAMPS study (see reference). This study was designed to determine if immediate initiation of therapy with Interferon Beta-1a (AVONEX) after a first attack of multiple sclerosis (MS) continues to delay the development of further attacks (CDMS) and the development of neurological disability over a 10 year period of observation. The initial 5 year extension study, called CHAMPIONS5, reported that immediate initiation of interferon Beta-1a (AVONEX) after a first attack of MS continued to delay the development of CDMS and lowered relapse rates compared to delayed initiation of disease modifying treatment (usually with AVONEX) either at the time of a second attack or at the end of the phase III study (24 months). The study was extended to 10 years to determine if these effects are sustained and result in less long term permanent disability.
Study identification
- NCT ID
- NCT00179478
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 155 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2001 (Type not available)
- Primary completion
- Mar 2009 (Actual)
- Completion
- Mar 2009 (Actual)
- Last update posted
- Sep 6, 2017
2001 – 2009
United States locations
- U.S. sites
- 20
- U.S. states
- 15
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| MS Treatment Center at Griffin Hospital | Derby | Connecticut | 06418 | — |
| Jaeb Center for Health Research | Tampa | Florida | 33647 | — |
| MS Center of Atlanta | Atlanta | Georgia | 30327 | — |
| Beta Research, Inc | Elk Grove | Illinois | 60007 | — |
| University of Iowa College of Medicine | Iowa City | Iowa | 52242 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Michigan State University | East Lansing | Michigan | 48824 | — |
| St. Louis University Health Sciences Center | St Louis | Missouri | 63110 | — |
| Jacobs Neurological Institute | Buffalo | New York | 14203 | — |
| University of Rochester | Rochester | New York | 14642 | — |
| Carolinas Medical Center - MS Center | Charlotte | North Carolina | 28207 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| The Ohio State University | Columbus | Ohio | 43210 | — |
| The Neurology Group | Norristown | Pennsylvania | 19401 | — |
| Univeristy of Pennsylvania Medical Center | Philadelphia | Pennsylvania | 19104 | — |
| Allegheny Neurological Associates | Pittsburgh | Pennsylvania | 15212 | — |
| Univeristy of Texas Houston Health Science Center | Houston | Texas | 77030 | — |
| Virginia Commonwealth University/Medical College of Virginia | Richmond | Virginia | 23219 | — |
| Neurological Associates, Inc. | Richmond | Virginia | 23230 | — |
| Marshfield Clinic | Marshfield | Wisconsin | 54449 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00179478, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 6, 2017 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00179478 live on ClinicalTrials.gov.